Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy

Background: Selecting patients who potentially benefit from immune checkpoint inhibitors (ICIs) is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical expression on cancer cells or immune cells and next-generation sequencing-based tumor mutational burden (TMB) are hot spots in st...

Full description

Bibliographic Details
Main Authors: Meilin Jiang, Wenying Peng, Xingxiang Pu, Bolin Chen, Jia Li, Fang Xu, Liyu Liu, Li Xu, Yan Xu, Jun Cao, Qianzhi Wang, Kang Li, Jingyi Wang, Lin Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
non–small cell lung cancer
predictive biomarker
nivolumab
durvalumab
platelet-to-lymphocyte ratio
albumin
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00913/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00913/full

Similar Items